HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and announces $6 price target.